Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul;78(7):1758-1776.
doi: 10.1111/all.15740.

Patient-centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA-EAACI approach - ARIA-EAACI Task Force Report

Jean Bousquet  1   2   3 Mohamed H Shamji  4   5 Josep M Anto  6   7   8 Holger J Schünemann  9 G Walter Canonica  10   11 Marek Jutel  12   13 Stefano Del Giacco  14 Torsten Zuberbier  1   3 Oliver Pfaar  15 Joao A Fonseca  16   17 Bernardo Sousa-Pinto  16   17 Ludger Klimek  18   19 Wienczyslawa Czarlewski  20   21 Anna Bedbrook  21   22 Rita Amaral  16   17 Ignacio J Ansotegui  23 Sinthia Bosnic-Anticevich  24   25   26 Fulvio Braido  27   28 Claudia Chaves Loureiro  29 Bilun Gemicioglu  30 Tari Haahtela  31 Marek Kulus  32 Piotr Kuna  33 Maciej Kupczyk  33 Paolo M Matricardi  34 Frederico S Regateiro  35   36   37 Boleslaw Samolinski  38 Mikhail Sofiev  39 Sanna Toppila-Salmi  31 Arunas Valiulis  40 Maria Teresa Ventura  41   42 Cristina Barbara  43 Karl C Bergmann  1   3 Michael Bewick  44 Hubert Blain  45 Matteo Bonini  4   46   47 Louis-Philippe Boulet  48 Rodolphe Bourret  49 Guy Brusselle  50 Luisa Brussino  51   52 Roland Buhl  53 Victoria Cardona  54   55 Thomas Casale  56 Lorenzo Cecchi  57 Denis Charpin  58 Ivan Cherrez-Ojeda  59   60 Derek K Chu  9 Cemal Cingi  61 Elisio M Costa  62 Alvaro A Cruz  63 Philippe Devillier  64 Stephanie Dramburg  65 Wytske J Fokkens  66 Maia Gotua  67 Enrico Heffler  10   11 Zhanat Ispayeva  68 Juan Carlos Ivancevich  69 Guy Joos  50 Igor Kaidashev  70 Helga Kraxner  71 Violeta Kvedariene  72   73 Désirée E Larenas-Linnemann  74 Daniel Laune  75 Olga Lourenço  76 Renaud Louis  77   78 Mika Makela  31 Michael Makris  79 Marcus Maurer  1   3 Erik Melén  80   81 Yann Micheli  75 Mario Morais-Almeida  82 Joaquim Mullol  83   84 Marek Niedoszytko  85 Robyn O'Hehir  86 Yoshitaka Okamoto  87   88 Heidi Olze  89   90 Nikolaos G Papadopoulos  91 Alberto Papi  92 Vincenzo Patella  93   94   95 Benoit Pétré  96 Nhân Pham-Thi  97   98   99 Francesca Puggioni  100 Santiago Quirce  101 Nicolas Roche  102 Philip W Rouadi  103   104 Ana Sá-Sousa  16   17 Hironori Sagara  105 Joaquin Sastre  106 Nicola Scichilone  107 Aziz Sheikh  108 Milan Sova  109 Charlotte Suppli Ulrik  110   111 Luis Taborda-Barata  112   113 Ana Todo-Bom  114 Maria J Torres  115 Ioanna Tsiligianni  116   117 Omar S Usmani  4   118 Erkka Valovirta  119 Tuula Vasankari  120   121 Rafael José Vieira  16   17 Dana Wallace  122 Susan Waserman  123 Mihaela Zidarn  124   125 Arzu Yorgancioglu  126 Luo Zhang  127 Tomas Chivato  128 Markus Ollert  129   130
Affiliations
Free article
Review

Patient-centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA-EAACI approach - ARIA-EAACI Task Force Report

Jean Bousquet et al. Allergy. 2023 Jul.
Free article

Abstract

Biomarkers for the diagnosis, treatment and follow-up of patients with rhinitis and/or asthma are urgently needed. Although some biologic biomarkers exist in specialist care for asthma, they cannot be largely used in primary care. There are no validated biomarkers in rhinitis or allergen immunotherapy (AIT) that can be used in clinical practice. The digital transformation of health and health care (including mHealth) places the patient at the center of the health system and is likely to optimize the practice of allergy. Allergic Rhinitis and its Impact on Asthma (ARIA) and EAACI (European Academy of Allergy and Clinical Immunology) developed a Task Force aimed at proposing patient-reported outcome measures (PROMs) as digital biomarkers that can be easily used for different purposes in rhinitis and asthma. It first defined control digital biomarkers that should make a bridge between clinical practice, randomized controlled trials, observational real-life studies and allergen challenges. Using the MASK-air app as a model, a daily electronic combined symptom-medication score for allergic diseases (CSMS) or for asthma (e-DASTHMA), combined with a monthly control questionnaire, was embedded in a strategy similar to the diabetes approach for disease control. To mimic real-life, it secondly proposed quality-of-life digital biomarkers including daily EQ-5D visual analogue scales and the bi-weekly RhinAsthma Patient Perspective (RAAP). The potential implications for the management of allergic respiratory diseases were proposed.

Keywords: ARIA; EAACI; apps; digital health; rhinitis.

PubMed Disclaimer

References

REFERENCES

    1. Agache I. Severe asthma phenotypes and endotypes. Semin Immunol. 2019;46:101301. doi:10.1016/j.smim.2019.101301
    1. Breiteneder H, Peng YQ, Agache I, et al. Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma. Allergy. 2020;75(12):3039-3068. doi:10.1111/all.14582
    1. Porpodis K, Tsiouprou I, Apostolopoulos A, et al. Eosinophilic asthma, phenotypes-Endotypes and current biomarkers of choice. J Pers Med. 2022;12(7):1093. doi:10.3390/jpm12071093
    1. Diamant Z, Vijverberg S, Alving K, et al. Toward clinically applicable biomarkers for asthma: an EAACI position paper. Allergy. 2019;74(10):1835-1851. doi:10.1111/all.13806
    1. Radzikowska U, Baerenfaller K, Cornejo-Garcia JA, et al. Omics technologies in allergy and asthma research: an EAACI position paper. Allergy. 2022;77(10):2888-2908. doi:10.1111/all.15412

Publication types